Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma

27 Nov 2019

Abstract excerpt

BACKGROUND: Euchromatic histone-lysine-N-methyltransferases 1 and 2 (EHMT1/2, aka GLP/G9A) catalyze dimethylation of histone H3 lysine 9 (H3K9me2) and have roles in epigenetic silencing of gene expression. EHMT1/2 also have direct roles in DNA repair and are implicated in chemoresistance in several cancers. Resistance to chemotherapy and PARP inhibitors (PARPi) is a major cause of mortality in high-grade serous...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Genomics and Chromatin Dynamics
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31775874
DOI: 10.1186/s13148-019-0758-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinomaPMID 31775874Read ↗

Targeting BRPF3 moderately reverses olaparib resistance in high grade serous ovarian carcinomaSemantic proximity Read ↗

Demethylating agents drive PARP inhibitor resistance in ovarian carcinomas with BRCA1 gene silencingSemantic proximity Read ↗

Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian CarcinomaSemantic proximity Read ↗

Characterization of a RAD51C -silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistanceSemantic proximity Read ↗

Combinatory EHMT and PARP inhibition induces an interferon response and a CD8 T cell-dependent tumor regression in PARP inhibitor-resistant modelsSemantic proximity Read ↗

High EMSY expression defines a BRCA‐like subgroup of high‐grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinumSemantic proximity Read ↗

Epigenetic and Genomic Hallmarks of PARP-Inhibitor Resistance in Ovarian Cancer PatientsSemantic proximity Read ↗

Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell linesSemantic proximity Read ↗

PARP inhibitors in ovarian cancer: Mechanisms of resistance and implications to therapySemantic proximity Read ↗

Decoding the Genomic and Functional Landscape of Emerging Subtypes in Ovarian CancerSemantic proximity Read ↗

EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent MannerSemantic proximity Read ↗

Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.